Shire sells US otc portfolio

Published: 3-Jan-2003

UK-based Shire Pharmaceuticals Group has sold its US otc products portfolio to an associated company of Purdue Pharma for US$72m (€69m). The portfolio consists of four products: Colace; Peri-Colace; Slow Mag; and mineral oil.


UK-based Shire Pharmaceuticals Group has sold its US otc products portfolio to an associated company of Purdue Pharma for US$72m (€69m). The portfolio consists of four products: Colace; Peri-Colace; Slow Mag; and mineral oil.

The otc products were acquired as part of the Roberts Pharmaceuticals purchase in 1999. However, this business has not been core to Shire's global strategy, and with this transaction,Shire is completing its exit from all otc activities to concentrate on its core strategy based on r&d combined with in-licensing and a focus on eight key pharmaceutical markets.

You may also like